litlas
Log inCreate account

Mark J. Ratain

Active 1986–2025

156
Papers
28,041
Citations
90
h-index
148
i10-index

Citations

Citations per year for Mark J. Ratain1956: 1 citations1977: 1 citations1987: 1 citations1988: 2 citations1989: 2 citations1990: 8 citations1991: 6 citations1992: 8 citations1993: 10 citations1994: 8 citations1995: 13 citations1996: 10 citations1997: 13 citations1998: 36 citations1999: 41 citations2000: 69 citations2001: 77 citations2002: 122 citations2003: 114 citations2004: 117 citations2005: 190 citations2006: 220 citations2007: 246 citations2008: 217 citations2009: 274 citations2010: 274 citations2011: 299 citations2012: 347 citations2013: 296 citations2014: 300 citations2015: 272 citations2016: 237 citations2017: 186 citations2018: 194 citations2019: 639 citations2020: 615 citations2021: 618 citations2022: 466 citations2023: 296 citations2024: 438 citations2025: 228 citations2026: 5 citations1957–1976: no citations, so these years are not shown1978–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,364 citing papers, 33.4% of this breakdownChina: 756 citing papers, 7.5% of this breakdownUnited Kingdom: 609 citing papers, 6% of this breakdownGermany: 477 citing papers, 4.7% of this breakdownItaly: 445 citing papers, 4.4% of this breakdownCanada: 401 citing papers, 4% of this breakdownNetherlands: 377 citing papers, 3.7% of this breakdownFrance: 366 citing papers, 3.6% of this breakdownJapan: 302 citing papers, 3% of this breakdownSpain: 268 citing papers, 2.7% of this breakdownAustralia: 261 citing papers, 2.6% of this breakdownSwitzerland: 205 citing papers, 2% of this breakdown
0%33.4%Other 22.4%

Institutions

Fields

  • Medicine54%
  • Biochemistry, Genetics and Molecular Biology24.8%
  • Pharmacology, Toxicology and Pharmaceutics6.7%
  • Economics, Econometrics and Finance4.7%
  • Immunology and Microbiology2.2%
  • Mathematics1.8%
  • Other5.8%

Topics

  • Lung Cancer Treatments and Mutations5.4%
  • Cancer Genomics and Diagnostics3.7%
  • Lung Cancer Research Studies3.3%
  • Pharmacogenetics and Drug Metabolism3%
  • Cancer therapeutics and mechanisms2.7%
  • Cancer Immunotherapy and Biomarkers2.4%
  • Other79.5%

Coauthors

All papers

Open in search
  1. Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

    Authors: Jonas A. de Souza, Bonnie J. Yap, Kristen Wroblewski, Victoria Blinder, Fabiana S. Araújo, Fay J. Hlubocky, Hyung J. Cho, Jeremy O’Connor, Bruce Brockstein, Mark J. Ratain, Christopher K. Daugherty, David Cella - Cancer 2016 cited by 882

  2. The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

    Authors: Jonas A. de Souza, Bonnie J. Yap, Fay J. Hlubocky, Kristen Wroblewski, Mark J. Ratain, David Cella, Christopher K. Daugherty - Cancer 2014 cited by 649

  3. Tumour heterogeneity in the clinic

    Authors: Philippe L. Bédard, Aaron R. Hansen, Mark J. Ratain, Lillian L. Siu - Nature 2013 cited by 1,230

  4. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

    Authors: Jason J. Luke, Jeffrey M. Lemons, Theodore Karrison, Sean P. Pitroda, J.M. Melotek, Yuanyuan Zha, Hania Al‐Hallaq, Ainhoa Arina, Nikolai N. Khodarev, Linda Janisch, Paul J. Chang, Jyoti D. Patel, Gini F. Fleming, John W. Moroney, Manish Sharma, Julia White, Mark J. Ratain, Thomas F. Gajewski, Ralph R. Weichselbaum, Steven J. Chmura - Journal of Clinical Oncology 2018 cited by 587

  5. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Authors: Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2010 cited by 4,504

  6. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Authors: Daniel Vilarim Araújo, Alastair Greystoke, SE Bates, A. Bayle, Emiliano Calvo, Luís Castelo-Branco, Johann S. de Bono, Alexander Drilon, Elena Garralda, Percy Ivy, Olga Kholmanskikh, Ignacio Melero, George Pentheroudakis, James J. B. Petrie, Ruth Plummer, Santiago Ponce, S. Postel-Vinay, L.L. Siu, Anna Spreafico, Anastasios Stathis, Neeltje Steeghs, Christina Yap, Timothy A. Yap, Mark J. Ratain, Lesley Seymour - Annals of Oncology 2022 cited by 97

  7. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

    Authors: Matthew P. Goetz, Katrin Sangkuhl, Henk‐Jan Guchelaar, Matthias Schwab, Michael A. Province, Michelle Whirl‐Carrillo, W. Fraser Symmans, Howard L. McLeod, Mark J. Ratain, Hitoshi Zembutsu, Andrea Gaedigk, Ron HN van Schaik, James N. Ingle, Kelly E. Caudle, Teri E. Klein - Clinical Pharmacology & Therapeutics 2018 cited by 324

  8. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

    Authors: Russell Z. Szmulewitz, Cody J. Peer, Abiola Ibraheem, Elia Martinez, Mark Kozloff, Bradley Curtis Carthon, R. Donald Harvey, Paul A. S. Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D. Figg, Walter M. Stadler, Mark J. Ratain - Journal of Clinical Oncology 2018 cited by 181

  9. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors.

    Authors: Anthony W. Tolcher, Kyriakos P. Papadopoulos, Amita Patnaik, Drew Rasco, D.Y. Freire Martinez, Debra L. Wood, B. Fielman, Manish Sharma, Linda Janisch, Bob D. Brown, Pankaj Bhargava, Mark J. Ratain - Journal of Clinical Oncology 2015 cited by 116

  10. Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

    Authors: Federico Innocenti, Samir D. Undevia, Lalitha Iyer, Pei Xian Chen, Soma Das, Masha Kocherginsky, Theodore Karrison, Linda Janisch, Jacqueline Ramı́rez, Charles M. Rudin, Everett E. Vokes, Mark J. Ratain - Journal of Clinical Oncology 2004 cited by 954

  11. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

    Authors: Corey C. Foster, Gini F. Fleming, Theodore Karrison, Chih‐Yi Liao, Ami V. Desai, John W. Moroney, Mark J. Ratain, Rita Nanda, Blasé N. Polite, Olwen Hahn, Peter H. O’Donnell, Everett E. Vokes, Hedy L. Kindler, Robyn D. Hseu, Linda Janisch, Julia Dai, Mark D. Hoffman, Ralph R. Weichselbaum, Sean P. Pitroda, Steven J. Chmura, Jason J. Luke - Clinical Cancer Research 2021 cited by 42

  12. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

    Authors: Patricia LoRusso, Mark J. Ratain, Toshihiko Doi, Drew Rasco, Maja J.A. de Jonge, Víctor Moreno, Benedito A. Carneiro, Lot A. Devriese, Adam M. Petrich, Dimple Modi, Susan E. Morgan-Lappe, Silpa Nuthalapati, Monica Motwani, Martin Dunbar, Jaimee Glasgow, Bruno C. Medeiros, Emiliano Calvo - Investigational New Drugs 2022 cited by 29

  13. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

    Authors: Razelle Kurzrock, Steven I. Sherman, Douglas W. Ball, Arlene A. Forastiere, Roger B. Cohen, Ranee Mehra, David G. Pfister, Ezra E.W. Cohen, Linda Janisch, Forlisa Nauling, David S. Hong, Chaan S. Ng, Lei Ye, Robert F. Gagel, John Frye, Thomas Müller, Mark J. Ratain, Ravi Salgia - Journal of Clinical Oncology 2011 cited by 551

  14. Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer

    Authors: Rachel Humphrey, Laura Brockway-Lunardi, Damian Bonk, Kathleen M. Dohoney, James H. Doroshow, Sandra J. Meech, Mark J. Ratain, Suzanne L. Topalian, Drew M. Pardoll - JNCI Journal of the National Cancer Institute 2011 cited by 136

  15. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    Authors: Tim Eisen, T. Ahmad, Keith T. Flaherty, Martin Gore, Stan B. Kaye, Richard Marais, I. Gibbens, Samuel Hackett, Maggie James, Lynn M. Schuchter, Katherine L. Nathanson, Chenjing Xia, Ronit Simantov, Brian Schwartz, Melanie Poulin-Costello, Peter J. O’Dwyer, Mark J. Ratain - British Journal of Cancer 2006 cited by 636

  16. Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement

    Authors: Laura A. Levit, Jeffrey Peppercorn, Alda L. Tam, Jonathan M. Marron, Debra Mathews, Kathryn Levit, Nancy Roach, Mark J. Ratain - Journal of Clinical Oncology 2019 cited by 53

  17. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?

    Authors: Mark J. Ratain, Ian F. Tannock, Allen S. Lichter - Journal of Clinical Oncology 2021 cited by 41

  18. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

    Authors: Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain - The Journal of Clinical Pharmacology 2021 cited by 33

  19. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    Authors: Lalitha Iyer, Soma Das, Linda Janisch, Min Wen, Jacqueline Ramı́rez, Theodore Karrison, Gini F. Fleming, Everett E. Vokes, Richard L. Schilsky, Mark J. Ratain - The Pharmacogenomics Journal 2002 cited by 712

  20. Pharmacogenomics: Challenges and Opportunities

    Authors: Dan M. Roden, Russ B. Altman, Neal L. Benowitz, David A. Flockhart, Kathleen M. Giacomini, Julie A. Johnson, Ronald M. Krauss, Howard L. McLeod, Mark J. Ratain, Mary V. Relling, Huijun Z. Ring, Alan R. Shuldiner, Richard M. Weinshilboum, Scott T. Weiss - Annals of Internal Medicine 2006 cited by 281

  21. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine

    Authors: Kathleen M. Giacomini, Sook Wah Yee, Taisei Mushiroda, Richard M. Weinshilboum, Mark J. Ratain, Michiaki Kubo - Nature Reviews Drug Discovery 2016 cited by 104

  22. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    Authors: Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer - Journal of Clinical Oncology 2006 cited by 1,030

  23. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.

    Authors: Harvey M. Golomb, Alice K. Jacobs, A Fefer, Howard Ozer, John F. Thompson, C. Portlock, Mark J. Ratain, David W. Golde, J. W. Vardiman, Jerome S. Burke - Journal of Clinical Oncology 1986 cited by 236

  24. Cancer pharmacogenomics: strategies and challenges

    Authors: Heather E. Wheeler, Michael L. Maitland, M. Eileen Dolan, Nancy J. Cox, Mark J. Ratain - Nature Reviews Genetics 2012 cited by 220